Department of Molecular Medicine, Royal College of Surgeons in Ireland (RCSI) Education and Research Centre, Beaumont Hospital, Dublin 9, Ireland.
Institut de Biologie Valrose (iBV), CNRS UMR7277, INSERM U1091, Bâtiment Sciences Naturelles, University of Nice Sophia Antipolis, Parc Valrose, F-06108 Nice, France.
Proc Natl Acad Sci U S A. 2017 Apr 18;114(16):4159-4164. doi: 10.1073/pnas.1702913114. Epub 2017 Apr 3.
The K channel KCNQ1 has been proposed as a tumor suppressor in colorectal cancer (CRC). We investigated the molecular mechanisms regulating KCNQ1:β-catenin bidirectional interactions and their effects on CRC differentiation, proliferation, and invasion. Molecular and pharmacologic approaches were used to determine the influence of KCNQ1 expression on the Wnt/β-catenin signaling and epithelial-to-mesenchymal transition (EMT) in human CRC cell lines of varying stages of differentiation. The expression of KCNQ1 was lost with increasing mesenchymal phenotype in poorly differentiated CRC cell lines as a consequence of repression of the KCNQ1 promoter by β-catenin:T-cell factor (TCF)-4. In well-differentiated epithelial CRC cell lines, KCNQ1 was localized to the plasma membrane in a complex with β-catenin and E-cadherin. The colocalization of KCNQ1 with adherens junction proteins was lost with increasing EMT phenotype. ShRNA knock-down of KCNQ1 caused a relocalization of β-catenin from the plasma membrane and a loss of epithelial phenotype in CRC spheroids. Overexpression of KCNQ1 trapped β-catenin at the plasma membrane, induced a patent lumen in CRC spheroids, and slowed CRC cell invasion. The KCNQ1 ion channel inhibitor chromanol 293B caused membrane depolarization, redistribution of β-catenin into the cytosol, and a reduced transepithelial electrical resistance, and stimulated CRC cell proliferation. Analysis of human primary CRC tumor patient databases showed a positive correlation between KCNQ1:KCNE3 channel complex expression and disease-free survival. We conclude that the KCNQ1 ion channel is a target gene and regulator of the Wnt/β-catenin pathway, and its repression leads to CRC cell proliferation, EMT, and tumorigenesis.
钾通道 KCNQ1 已被提议为结直肠癌(CRC)的肿瘤抑制因子。我们研究了调节 KCNQ1:β-catenin 双向相互作用及其对 CRC 分化、增殖和侵袭影响的分子机制。采用分子和药理学方法来确定 KCNQ1 表达对不同分化程度的人 CRC 细胞系中 Wnt/β-catenin 信号和上皮间质转化(EMT)的影响。随着低分化 CRC 细胞系中间充质表型的增加,KCNQ1 的表达丢失,这是由于 β-catenin:T 细胞因子(TCF)-4 对 KCNQ1 启动子的抑制所致。在分化良好的上皮 CRC 细胞系中,KCNQ1 与 β-catenin 和 E-cadherin 一起定位于质膜。随着 EMT 表型的增加,KCNQ1 与黏着连接蛋白的共定位丢失。KCNQ1 的 shRNA 敲低导致 β-catenin 从质膜重新定位,并导致 CRC 球体中上皮表型的丧失。KCNQ1 的过表达将 β-catenin 困在质膜上,在 CRC 球体中诱导出有孔管腔,并减缓 CRC 细胞侵袭。KCNQ1 离子通道抑制剂 chromanol 293B 引起质膜去极化、β-catenin 向细胞质重新分布以及跨上皮电阻降低,并刺激 CRC 细胞增殖。对人原发性 CRC 肿瘤患者数据库的分析表明,KCNQ1:KCNE3 通道复合物的表达与无病生存期呈正相关。我们得出结论,KCNQ1 离子通道是 Wnt/β-catenin 通路的靶基因和调节剂,其抑制导致 CRC 细胞增殖、EMT 和肿瘤发生。